Rather than purchasing individual vials, this bundle allows researchers to explore synergistic interactions across metabolic, regenerative, neuroendocrine, and anti-aging axes simultaneously
Here, I want to keep the focus on RA
The Lean Mass Paradox: Why GLP-1 Data Raised Red Flags In many randomized controlled trials on GLP-1 weight loss drugs, it appears that a disproportionate amount of weight loss comes from lean mass, on the order of 40% of weight loss as lean body mass
Coverage for weight loss specifically is still far from universal
Theoretically, berberine might have additive effects with antidiabetes drugs and increase the risk of hypoglycemia
Results from a phase 1 trial have supported further clinical evaluation with a dose-dependent WL up to 14.5% with AMG133 compared to 1.5% with placebo by day 85 [59]